Cargando…
Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose—the PP100–01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial
BACKGROUND: Paracetamol (acetaminophen) overdose (POD) is the commonest cause of acute liver failure in Europe and North America. Current treatment involves the use of the antidote N-acetylcysteine (NAC) in patients deemed at risk of liver damage. This regimen was introduced in the 1970s and has rem...
Autor principal: | Dear, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325794/ https://www.ncbi.nlm.nih.gov/pubmed/30621764 http://dx.doi.org/10.1186/s13063-018-3134-1 |
Ejemplares similares
-
Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
por: Karlsson, Jan Olof G., et al.
Publicado: (2019) -
Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)
por: Morrison, Emma E., et al.
Publicado: (2019) -
Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose
por: Pettie, Janice M., et al.
Publicado: (2019) -
Impact of Amending the Acetylcysteine Marketing Authorisation on Treatment of Paracetamol Overdose
por: Thompson, G., et al.
Publicado: (2013) -
Fomepizole should not be used more liberally in paracetamol overdose
por: Dear, James W.
Publicado: (2022)